EV Biomarker CTLA-4 Detection for Immunomodulatory Efficacy Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing EV preparations lack consistency and are not suitable for large-scale production, making it difficult to assess the immunomodulatory profile of EVs efficiently.
Innovation Solution
A method for assessing the therapeutic efficacy of EVs by detecting the presence of biomarkers such as CTLA-4, PD1, PD-L1, and PD-L2, allowing for evaluation of immunomodulatory efficacy without the need for laborious in vivo or in vitro assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If laborious in vivo or in vitro assays including mixed lymphocyte reaction assays are performed to assess immunomodulatory efficacy, then measurement precision is improved, but loss of time and device complexity increase
Solution Approach 1:
The patent extracts the essential information needed for efficacy assessment from complex functional assays and concentrates it into a single measurable parameter - the presence of CTLA-4 biomarker on EV surface. This extraction allows rapid assessment without performing complete functional assays, thus reducing time loss while maintaining assessment validity.
Solution Approach 2:
The patent introduces CTLA-4 as an intermediary biomarker that mediates between the complex immunomodulatory function and the assessment process. Instead of directly measuring complex immune responses through laborious assays, the biomarker serves as a proxy indicator that correlates with immunomodulatory efficacy, enabling fast and simple assessment.
2Measurement precision
If laborious in vivo or in vitro assays including mixed lymphocyte reaction assays are performed to assess immunomodulatory efficacy, then measurement precision is improved, but device complexity and ease of operation worsen
Solution Approach 1:
The patent extracts the essential information needed for efficacy assessment from complex functional assays and concentrates it into a single measurable parameter - the presence of CTLA-4 biomarker on EV surface. This extraction allows rapid assessment without performing complete functional assays, thus reducing time loss while maintaining assessment validity.
Solution Approach 2:
The patent introduces CTLA-4 as an intermediary biomarker that mediates between the complex immunomodulatory function and the assessment process. Instead of directly measuring complex immune responses through laborious assays, the biomarker serves as a proxy indicator that correlates with immunomodulatory efficacy, enabling fast and simple assessment.
3Manufacturing precision
If conventional EV production methods are used, then manufacturing precision is maintained, but productivity and ease of manufacture worsen
Solution Approach 1:
The patent implements a feedback mechanism where the presence of CTLA-4 biomarker is used as a quality control indicator to assess and select EV preparations. This feedback allows rapid evaluation of production batches, enabling optimization of production processes for large-scale manufacturing while maintaining precision through biomarker-based quality control.
Solution Approach 2:
The patent changes the assessment parameter from complex functional assay results to a simple binary presence/absence detection of CTLA-4 biomarker. This parameter change enables scalability and automation in manufacturing processes, improving productivity while maintaining manufacturing precision through standardized biomarker-based quality control.
Data Source
AI summary
The present invention is based on a correlation found for the presence of the biomarker protein Cytotoxic T-lymphocyte protein 4, also known as CD152 or CTLA-4, on or in EVs, to their immunomodulatory efficacy. Hence, the invention provides a method for assessing the therapeutic efficacy of an EV or an EV-preparation by detecting the biomarker CTLA-4 in such EVs or EV-preparations. Furthermore, the invention provides a method for assessing the therapeutic efficacy of an EV or an EV-preparation by detecting at least one biomarker selected from the group of CTLA-4, PD1, PD-L1 and PD-L2 in the EV or EV-preparation. The method of the invention allows for an evaluation of the immunomodulatory efficacy of said EV preparations without the need of performing laborious functional in vivo or in vitro assays including mixed lymphocyte reaction assays. In three additional aspects of the invention, alternative methods for producing therapeutically active EVs or EV-preparations are provided. Further provided are therapeutically active EVs or EV preparations produced by the methods of the invention and their use in medicine, for example in the manufacturing of immunomodulatory medicaments.